CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is hiring and looking for a Manager, Office of Compliance and Oversight (OCO) and a Quality Leader, Office of Clinical Trials Management (OCTM) to join our team at the central operations office at Queen's University.
Meet Martina Wood a breast cancer survivor and a member of the CCTG breast committee. Our teams are proud to work with volunteers like Martina who ensure the patient voice is part of our clinical trial development.
The Canadian Cancer Trials Group (CCTG), at Queen’s University, asks and finds evidence-based answers to critical questions about the best treatment options for the 225,000 Canadians diagnosed with cancer each year. Innovations proven to be effective through CCTG led clinical trials have set new standards of care that guide treatment decisions for patients today and tomorrow: curing disease, preventing recurrence, saving lives, and improving quality of life. See full article here.
A paper has recently been published in Current Oncology outlining the incorporation of patient engagement in the development of clinical trial at the Canadian Cancer Trials Group (CCTG).
A recent abstract presented at GI ASCO 2021: Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
The UK National Cancer Research Institute (NCRI) has cited the CCTG PR13 study (RADICALS-RT) as one of their top three achievements of the year in their 2019-2020 annual report! https://www.ncri.org.uk/wp-content/uploads/NCRI-Prostate-Group-Annual-Report-2019-20.pdf
CCTG SR7: A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS-2), has been centrally activated.
For our Canadian member sites a COVID-19 reminder to keep the CCTG updated on trial activities at your site.
